Slide 1: Novocure (NVCR) company overview updated August 2016
Novocure (NVCR) company overview updated August 2016 Exhibit 99.1
Slide 2: Forward-looking statements
forward-looking statements This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of its lead product candidate, Optune, for a number of oncology i
Slide 3: Novocure at a glance
Novocure at a glance Global oncology company founded in 2000 Pioneering a therapy called Tumor Treating Fields (TTFields) for solid tumor cancers Executing on strategic growth Transforming the current standard of care for glioblastoma (GBM) Broad applicability of TTFields across additional solid tum
Slide 4: Novel, anti-mitotic solid tumor cancer therapy
NOVEL, ANTI-MITOTIC SOLID TUMOR CANCER THERAPY tumor treating fields surgery radiation pharmacological treatments tumor treating fields (TTFIELDS) Most frequently employed therapy Reduces size of a tumor prior to initiation of additional therapies Kills cells when delivered at high doses Injures hea
Slide 5: Treatment does not harm normal cell growth
Treatment does not harm normal cell growth frequency tuned to specific cell types Normal Intestine ~50 kHz Pancreatic Cancer 150 kHz NSCLC 150 kHz Ovarian Cancer 200 kHz GBM 200 kHz EFFECTS ON CELLS ARE FREQUENCY SPECIFIC AND INVERSELY RELATED TO CELL SIZE
Slide 6: Non-invasive, portable delivery
non-invasive, portable delivery Battery or wall-powered electric field generator Single-use transducer arrays replaced 2–3 times a week
Slide 7: Second generation Optune System
second generation Optune System Half the size and weight of the first generation Optune system – weighing only 2.7 pounds CE marked and available in Europe since 2015 Received FDA approval of PMA supplement on July 13, 2016 Converting all U.S. patients throughout Q3 2016
Slide 8: Home use, quality of life maintained
home use, quality of life maintained Should be used at least 18 hours a day Mild side-effect profile with no known systemic toxicity
Slide 9: Extensive preclinical research
extensive preclinical research 15+ years of research and multiple peer-reviewed publications Deep understanding of the underlying mechanism
Slide 10: Monotherapy treatment for recurrent GBM
MONOTHERAPY TREATMENT FOR RECURRENT GBM Initial FDA approval in 2011 Overall survival times for patients treated with TTFields alone and active chemotherapy were 6.6 months and 6.0 months, respectively Patient compliance is important for successful outcomes Long-term follow-up indicated that 8% of p
Slide 11: Combination therapy for newly diagnosed GBM
combination therapy for newly diagnosed GBM EF-14 phase 3 pivotal trial initiated in 2009 A prospective, multicenter trial of TTFields together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM 80 centers; 695 newly diagnosed GBM patients randomized 2:1 (TTFields
Slide 12: EF-14 progression free survival
intent-to-treat population EF-14 progression free survival TTFIELDS + TMZ (n=210) TMZ ALONE (n=105) Median PFS, months 7.2 4.0 HR and p value HR=0.62, p=0.001
Slide 13: EF-14 overall survival
as-treated population EF-14 overall survival TTFIELDS + TMZ (n=196) TMZ ALONE (n=84) Median OS, months 20.5 15.6 HR and p value HR=0.66, p=0.004 2-year survival 48% 32% p value p=0.0058
Slide 14: Combination treatment for newly diagnosed GBM
combination treatment for newly diagnosed GBM FDA approval on October 5, 2015 Indications For Use Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of ad
Slide 15: JAMA publication on December 15, 2015
combination treatment for newly diagnosed GBM JAMA publication on December 15, 2015
Slide 16: NCCN Clinical Practice Guidelines updated July 2016
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) updated July 2016 National Comprehensive Cancer Network® (NCCN®) published updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers in July 20161 Alternating electric field therapy (Opt
Slide 17: Direct to patient distribution model
direct to patient distribution model PHYSICIAN ECONOMICS Physician can bill for incremental services Physician does not have to buy and hold inventory Physician does not take on reimbursement risk for Optune therapy Physician sends prescription order to Novocure Physician or Novocure uses NovoTAL Sy
Slide 18: Q2 2016 global operating statistics
q2 2016 global operating statistics q2 2016 q2 2015 % GROWTH q1 2016 % GROWTH Prescriptions 657 428 54% 755 -13% United States 547 390 40% 684 -20% Germany, Switzerland and other EMEA Markets 110 38 189% 71 55% Japan - - n/a - n/a Active patients at period end 891 425 110% 797 12% United States 736
Slide 19: Significant active patient growth
significant active patient growth Global active patients at period end >397% ACTIVE PATIENT GROWTH SINCE Q3 2014 Global certified centers 212 262 309 367 492 584 Global sales colleagues 17 20 30 33 44 50 Nov. 2014 EF-14 presentation Oct. 2015 FDA approval
Slide 20: Established reimbursement history
established reimbursement history As of June 30, 2016, positive coverage policies in place for > 116 million lives More than 60% of all patients with commercial healthcare plans now have access to Optune under coverage policies issued by their plan Appealing Medicare fee-for-service denials, impacti
Slide 21: Q2 2016 selected financial highlights
q2 2016 selected financial highlights U.S. DOLLARS IN THOUSANDS q2 2016 q2 2015 % GROWTH Net revenues $ 17,919 $ 6,543 174% Cost of revenues 9,797 4,750 106% Impairment of field equipment 6,412 - Gross profit 1,710 1,793 -5% Research, development and clinical trials 11,318 12,765 -11% Sales and mark
Slide 22: Total addressable GBM market
total addressable GBM market >$2.5B United States 12,500 GBM incidence 9,300 medically eligible for treatment $1.2 Billion TAM Target EU Markets 13,500 GBM incidence 10,000 medically eligible for treatment $1.3 Billion TAM Japan 1,500 GBM incidence 1,100 medically eligible for treatment $139 Million
Slide 23: Entering new markets
entering new markets Commercial activity focuses initially on establishing required in-market infrastructure Certifying physicians and prescribing centers Communicating information about TTFields to the medical community Securing defined reimbursement pathway Once established, commercial efforts tur
Slide 24: Broad applicability to solid tumors
broad applicability to solid tumors
Slide 25: Multiple ongoing clinical trials
multiple ongoing clinical trials
Slide 26: Anticipated 2016 milestones
anticipated 2016 milestones Increase positive coverage policies of Optune INNOVATE phase 2 pilot trial last patient in PANOVA phase 2 pilot trial last patient in FDA approval of second generation Optune System NCCN Guidelines® update METIS phase 3 pivotal trial first patient in LUNAR phase 3 pivotal
Slide 27: Appendix
appendix
Slide 28: Physical, observable mechanism of action
physical, observable mechanism of action Anti-mitotic mechanism of action is based on disruption of key electrically charged molecules essential to the mitotic process by which all cells divide Interference with these key molecules leads to cell death through multiple pathways For example, TTFields
Slide 29: Physical, observable mechanism of action
physical, observable mechanism of action Anti-mitotic mechanism of action is based on disruption of key electrically charged molecules essential to the mitotic process by which all cells divide Interference with these key molecules leads to cell death through multiple pathways For example, TTFields
Slide 30: Complementary to other treatment modalities
complementary to other treatment modalities Clinical pipeline focuses on studying TTFields in combination with current standards of care Pre-clinical studies have demonstrated that TTFields can offer additive or synergistic benefits in combination with radiation, certain chemotherapy and immunothera
Slide 31: Monotherapy treatment for recurrent GBM: EF-11 overall survival
MONOTHERAPY TREATMENT FOR RECURRENT GBM EF-11 overall survival OPTUNE (n=120) CHEMOTHERAPY (n=117) Median OS, months 6.6 6.0 HR and p value HR=0.86, p=0.27 4-year survival 8% 0% n = 85 n = 13
Slide 32: Significant active patient growth: United States
significant active patient growth United States active patients at period end >332% ACTIVE PATIENT GROWTH SINCE Q3 2014 U.S. certified centers 177 196 215 244 347 409 U.S. sales colleagues 16 18 27 30 38 41 Nov. 2014 EF-14 presentation Oct. 2015 FDA approval
Slide 33: Significant active patient growth: Germany, Switzerland and other EMEA
significant active patient growth Germany, Switzerland and other EMEA markets active patients at period end >16x ACTIVE PATIENT GROWTH SINCE Q3 2014 EMEA certified centers 35 44 52 62 70 85 EMEA sales colleagues - - 1 1 4 7 Nov. 2014 EF-14 presentation Oct. 2015 FDA approval
Slide 34: Active patients drive revenue
Increase or decrease in active patients in any given period reflects the number of new patients less the number of patients discontinuing therapy The conversion of prescriptions to new patients is driven by the prescription fill rate and the time to fill the prescription The rate of patients discont
Slide 35: Brain metastases METIS phase 3 pivotal trial
BRAIN METASTASES METIS phase 3 pivotal trial initiated in 2016 A prospective, randomized controlled, multicenter trial testing efficacy, safety and neurocognitive outcomes of TTFields at 150 kHz following stereotactic radiosurgery in advanced non-small cell lung cancer patients with 1-10 brain metas
Slide 36: Non-small cell lung cancer phase 2 pilot EF-15 trial
non-small cell lung cancer phase 2 pilot EF-15 trial A prospective, open label, single-arm, non-randomized, multicenter study of TTFields at 150 kHz to estimate efficacy and determine safety together with pemetrexed in pretreated patients with locally advanced non-small cell lung cancer versus histo
Slide 37: Non-small cell lung cancer LUNAR phase 3 trial
non-small cell lung cancer Based on phase 2 pilot EF-15 trial data, currently designing a phase 3 pivotal trial (LUNAR) to possibly capitalize on potential synergies with taxane-based chemotherapies and potential additivity with PD-1 inhibitors Subject to FDA approval of the IDE, LUNAR phase 3 trial
Slide 38: Pancreatic cancer phase 2 pilot PANOVA trial
pancreatic cancer phase 2 pilot PANOVA trial A prospective, open label, single-arm, non-randomized, multicenter study testing feasibility, safety and preliminary efficacy of TTFields at 150 kHz together with gemcitabine or gemcitabine plus nab-paclitaxel in patients with advanced pancreatic cancer v
Slide 39: Pancreatic cancer PANOVA first cohort results
pancreatic cancer phase 2 pilot PANOVA trial First cohort analysis presented at ASCO GI in January 2016, demonstrating PFS and OS of patients treated with TTFields with gemcitabine were more than double those of gemcitabine-alone historical controls First cohort subgroup analysis presented at ASCO i
Slide 40: Recurrent ovarian cancer phase 2 pilot INNOVATE trial
RECURRENT OVARIAN CANCER phase 2 pilot INNOVATE trial A prospective, open label, single-arm, non-randomized, multicenter study testing feasibility, safety, toxicity and preliminary efficacy of TTFields at 200 kHz together with weekly paclitaxel in patients with recurrent ovarian cancer versus histor
Slide 41: Mesothelioma phase 2 pilot STELLAR trial
MESOTHELIOMA phase 2 pilot STELLAR trial A prospective, open label, single-arm, non-randomized, multicenter study testing safety and preliminary efficacy of TTFields at 150 kHz together with pemetrexed and cisplatin or carboplatin in patients with previously untreated malignant pleural mesothelioma
Slide 42: Daniel Torres, EF-11 clinical trial patient, and his family
Daniel Torres, EF-11 clinical trial patient, and his family
Slide 43: Daniel Torres and Mike Ambrogi, Novocure's COO
Daniel Torres, EF-11 clinical trial patient, and Mike Ambrogi, Novocure’s COO
Slide 44: Maureen Colosimo, EF-14 clinical trial patient
Maureen Colosimo, EF-14 clinical trial patient